Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

被引:30
|
作者
Matsuda, Satoru [1 ]
Kawakubo, Hirofumi [1 ]
Okamura, Akihiko [2 ]
Takahashi, Keita [2 ]
Toihata, Tasuku [2 ]
Takemura, Ryo [3 ]
Mayanagi, Shuhei [1 ]
Hirata, Kenro [4 ]
Irino, Tomoyuki [1 ]
Hamamoto, Yasuo [4 ]
Takeuchi, Hiroya [5 ]
Watanabe, Masayuki [2 ]
Kitagawa, Yuko [1 ]
机构
[1] Keio Univ, Sch Med, Dept Surg, Tokyo, Japan
[2] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Surg Gastroenterol, Tokyo, Japan
[3] Keio Univ Hosp, Clin & Translat Res Ctr, Biostat Unit, Tokyo, Japan
[4] Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan
[5] Hamamatsu Univ, Sch Med, Dept Surg, Hamamatsu, Shizuoka, Japan
关键词
esophageal cancer; esophagectomy; multidisciplinary treatment; preoperative chemotherapy; CANCER-PATIENTS; CHEMORADIOTHERAPY; SURVIVAL; COMPLICATIONS;
D O I
10.1097/SLA.0000000000004436
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: This study aimed to elucidate the residual disease distribution and recurrence patterns in patients with ESCC responding to NAC. Summary Background Data: To appropriately plan a prospective trial for the organ preservation approach which includes additional chemoradiotherapy in patients who responded to NAC, the distribution of residual disease needs to be elucidated. Given that the residual tumor is located in the regional field, chemoradiotherapy can be safely added to eliminate the residual disease. Methods: Overall, 483 patients with resectable ESCC who received NAC followed by transthoracic esophagectomy at 2 high-volume centers were reviewed. The recurrence-free survival, overall survival (OS), and residual and recurrent tumor patterns were compared among the pathological responses. Results: Compared with nonpathological responders, pathological responders exhibited significantly longer recurrence-free survival [hazard ratio of Grade 1b/2/3 compared with Grade 0: 0.25 (P < 0.001)/0.17 (P < 0.001)/0.16 (P = 0.003)] and OS [hazard ratio of Grade 1b/2/3 compared with Grade 0: 0.26 (P < 0.001)/0.12 (P < 0.001)/0.11 (P = 0.003)]. In terms of the distribution of recurrence, the percentages of solitary recurrence in the regional field out of all recurrence was significantly higher in patients with Grade lb (60%)/2 (67%)/3 (67%) whereas less than 25% in Grade 0 or 1a. Conclusions: It was found that postoperative recurrence in responders occurred in the regional field mostly as a solitary lesion without the distant failure, indicating that the residual tumor cells can be eliminated by additional chemoradiotherapy.
引用
收藏
页码:298 / 304
页数:7
相关论文
共 50 条
  • [31] Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy
    Oguma, Junya
    Ishiyama, Koshiro
    Kurita, Daisuke
    Kanematsu, Kyohei
    Kubo, Kentaro
    Utsunomiya, Daichi
    Yamamoto, Shun
    Honma, Yoshitaka
    Kato, Ken
    Daiko, Hiroyuki
    ESOPHAGUS, 2023, 20 (02) : 215 - 224
  • [32] Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma
    Naoya Yoshida
    Yoshifumi Baba
    Hironobu Shigaki
    Kazuto Harada
    Masaaki Iwatsuki
    Yasuo Sakamoto
    Yuji Miyamoto
    Junji Kurashige
    Keisuke Kosumi
    Ryuma Tokunaga
    Masayuki Watanabe
    Hideo Baba
    International Journal of Clinical Oncology, 2016, 21 : 1071 - 1078
  • [33] Prognostic Significance of Stratification Using Pathological Stage and Response to Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
    Matsuda, Satoru
    Kawakubo, Hirofumi
    Okamura, Akihiko
    Takahashi, Keita
    Toihata, Tasuku
    Takemura, Ryo
    Mayanagi, Shuhei
    Takeuchi, Hiroya
    Watanabe, Masayuki
    Kitagawa, Yuko
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (13) : 8438 - 8447
  • [34] Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
    Chao, Yin-Kai
    Chang, Hsien-Kun
    Tseng, Chen-Kan
    Liu, Yun-Hen
    Wen, Yu-Wen
    DISEASES OF THE ESOPHAGUS, 2017, 30 (02):
  • [35] Neoadjuvant treatment for esophageal squamous cell carcinoma
    Baba, Yoshifumi
    Watanabe, Masayuki
    Yoshida, Naoya
    Baba, Hideo
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 6 (05) : 121 - 128
  • [36] Patterns of Recurrence After Robot-Assisted Minimally Invasive Esophagectomy in Esophageal Squamous Cell Carcinoma
    Yang, Yang
    Zhang, Hong
    Li, Bin
    Shao, Jinchen
    Liu, Zhichao
    Hua, Rong
    Li, Zhigang
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2023, 35 (03) : 615 - 624
  • [37] Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma
    Su, Xiao-Dong
    Zhang, Dong-Kun
    Zhang, Xu
    Lin, Peng
    Long, Hao
    Rong, Tie-Hua
    JOURNAL OF THORACIC DISEASE, 2014, 6 (07) : 949 - 957
  • [38] Recurrence timing and patterns incorporating lymph node status after neoadjuvant chemoradiotherapy plus esophagectomy for esophageal squamous cell carcinoma
    Liu, Guihong
    Hu, Binbin
    Chen, Tao
    Zhang, Xin
    Tang, Yu
    Chen, Qian
    Shi, Huashan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma
    Nakashima, Yuichiro
    Saeki, Hiroshi
    Hu, Qingjiang
    Tsuda, Yasuo
    Hisamatsu, Yuichi
    Ando, Koji
    Oki, Eiji
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2018, 38 (12) : 6809 - 6814
  • [40] Inflammatory and Nutritional Biomarkers in Patients With Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemotherapy and Radiation Therapy
    Huang, Chun Hou
    Chang, Bee Song
    Peng, Tai -Chu
    Peng, Yun-Hsin
    ONCOLOGY NURSING FORUM, 2024, 51 (02) : 177 - 192